These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35526575)

  • 1. Physiologically-Based Pharmacokinetic Modeling to Predict Methylphenidate Exposure Affected by Interplay Among Carboxylesterase 1 Pharmacogenetics, Drug-Drug Interactions, and Sex.
    Xiao J; Shi J; Thompson BR; Smith DE; Zhang T; Zhu HJ
    J Pharm Sci; 2022 Sep; 111(9):2606-2613. PubMed ID: 35526575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.
    Shi J; Wang X; Nguyen JH; Bleske BE; Liang Y; Liu L; Zhu HJ
    Biochem Pharmacol; 2016 Nov; 119():76-84. PubMed ID: 27614009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.
    Her L; Zhu HJ
    Drug Metab Dispos; 2020 Mar; 48(3):230-244. PubMed ID: 31871135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants.
    Lyauk YK; Stage C; Bergmann TK; Ferrero-Milliani L; Bjerre D; Thomsen R; Dalhoff KP; Rasmussen HB; Jürgens G
    Clin Transl Sci; 2016 Dec; 9(6):337-345. PubMed ID: 27754602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models.
    Qian Y; Markowitz JS
    Drug Metab Dispos; 2022 Jul; 50(7):968-979. PubMed ID: 35512806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of human CES1 genetic variation on enzyme activity assessed by ritalinic acid/methylphenidate ratios.
    Stage C; Dalhoff K; Rasmussen HB; Schow Guski L; Thomsen R; Bjerre D; Ferrero-Miliani L; Busk Madsen M; Jürgens G
    Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):54-61. PubMed ID: 30801959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects.
    Stage C; Jürgens G; Guski LS; Thomsen R; Bjerre D; Ferrero-Miliani L; Lyauk YK; Rasmussen HB; Dalhoff K;
    Br J Clin Pharmacol; 2017 Jul; 83(7):1506-1514. PubMed ID: 28087982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation.
    Shi J; Wang X; Nguyen J; Wu AH; Bleske BE; Zhu HJ
    Drug Metab Dispos; 2016 Apr; 44(4):554-9. PubMed ID: 26817948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects.
    Her LH; Wang X; Shi J; Choi HJ; Jung SM; Smith LS; Wu AH; Bleske BE; Zhu HJ
    Br J Clin Pharmacol; 2021 Dec; 87(12):4691-4700. PubMed ID: 33963573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition.
    Hu ZY; Edginton AN; Laizure SC; Parker RB
    Clin Pharmacokinet; 2014 Sep; 53(9):825-36. PubMed ID: 25103325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Dose Methylphenidate and Carboxylesterase 1 Genetic Variability in Patients With Attention-Deficit/Hyperactivity Disorder: A Case Series.
    Westerkamp AC; Pereira RR; Huitema VR; Kouwert EAM; Matic M; van Schaik RHN; Punt N; Schoevers RA; Touw DJ
    J Clin Psychopharmacol; 2024 Jan-Feb 01; 44(1):35-38. PubMed ID: 37851403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers.
    Wang X; Her L; Xiao J; Shi J; Wu AH; Bleske BE; Zhu HJ
    Clin Transl Sci; 2021 Jul; 14(4):1380-1389. PubMed ID: 33660934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof-of-Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism.
    Shi J; Xiao J; Wang X; Jung SM; Bleske BE; Markowitz JS; Patrick KS; Zhu HJ
    Clin Pharmacol Ther; 2022 Apr; 111(4):878-885. PubMed ID: 34743324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.
    Shi J; Wang X; Eyler RF; Liang Y; Liu L; Mueller BA; Zhu HJ
    Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):555-561. PubMed ID: 27228223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.
    Gong J; Iacono L; Iyer RA; Humphreys WG; Zheng M
    Br J Clin Pharmacol; 2018 Jun; 84(6):1335-1345. PubMed ID: 29469197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir.
    Zhang Q; Melchert PW; Markowitz JS
    Chem Biol Interact; 2022 Sep; 365():110097. PubMed ID: 35964681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.
    Zhu HJ; Appel DI; Peterson YK; Wang Z; Markowitz JS
    Toxicology; 2010 Apr; 270(2-3):59-65. PubMed ID: 20097249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.
    Wang X; Wang G; Shi J; Aa J; Comas R; Liang Y; Zhu HJ
    Pharmacogenomics J; 2016 Jun; 16(3):220-30. PubMed ID: 26076923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin.
    Qian Y; Gilliland TK; Markowitz JS
    Chem Biol Interact; 2020 Jan; 316():108914. PubMed ID: 31837295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review.
    Liu Y; Li J; Zhu HJ
    Expert Opin Drug Metab Toxicol; 2024 May; 20(5):377-397. PubMed ID: 38706437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.